Generated by AI
Standard BioTools Inc. is a life sciences tools company that develops and commercializes precision genomic and proteomic solutions for biomedical research. The company provides instrumentation, consumables, assays, software, and services used to study genes, proteins, cellular behavior, and tissue architecture across early discovery, translational, and clinical research workflows. Its product portfolio includes platforms for genomics, single-cell analysis, spatial biology, mass cytometry, and microfluidics, supporting applications in areas such as oncology, immunology, and biomarker discovery. Standard BioTools serves academic institutions, government laboratories, pharmaceutical companies, biotechnology firms, and clinical research organizations worldwide. The company focuses on helping researchers generate high-quality, reproducible biological data that can improve understanding of health and disease.
Website50 Milk Street
Boston, MA, 02109
United States
The latest articles about LAB.
BOSTON, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced it has entered into a definitive agreement to sell its Microfluidics business to ARCHIMED (“ARCHIMED”), a leading investment firm focused exclusively on healthcare industries. Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools, said, “ARCHIMED brings deep healthcare and life sciences expertise, a strong understanding of the mark
Summary of Oct 26's posts. Generated by AI.
Summary of Mar 1's posts. Generated by AI.
No summary yet.
Summary of Oct 26's posts. Generated by AI.
Investors talking about LAB also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.